Antares Pharma, Inc. Announces Launch of Tjet Needle-Free Injector System by Marketing Partner Teva Pharmaceutical Industries Limited

25 Aug 2009

·www.biospace.com

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) has launched its new Tjet™ needle-free injector system for the administration of human growth hormone (hGH). The Tjet™ device will be available exclusively in combination with the Teva hGH product Tev-Tropin® [somatropin (rDNA) for injection].

Organizations

Antares Pharma, Inc.

Teva Pharmaceutical Industries Ltd.

Indications

Targets

Drugs

Somatropin biosimilar (Dong-A ST Co., Ltd.)Somatropin(Ajinomoto Co., Inc.)Somatropin(Ferring Bv)

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.